<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33949169</PMID><DateCompleted><Year>2021</Year><Month>11</Month><Day>29</Day></DateCompleted><DateRevised><Year>2021</Year><Month>11</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1689-0035</ISSN><JournalIssue CitedMedium="Internet"><Volume>81</Volume><Issue>1</Issue><PubDate><Year>2021</Year></PubDate></JournalIssue><Title>Acta neurobiologiae experimentalis</Title><ISOAbbreviation>Acta Neurobiol Exp (Wars)</ISOAbbreviation></Journal><ArticleTitle>Effects of vitamin E on neurodegenerative diseases: an update.</ArticleTitle><Pagination><StartPage>21</StartPage><EndPage>33</EndPage><MedlinePgn>21-33</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.21307/ane-2021-003</ELocationID><Abstract><AbstractText>Vitamin E deficiency is associated with many neurological problems. Although the mechanisms of vitamin E action in neurodegenerative diseases are not clear, there are many possible mechanisms. Examples of such mechanisms are the protective effects of vitamin E against oxidative stress damage and its suppressive role in the expression of many genes involved in the development of neurodegeneration. Many studies have evaluated the relationship between vitamin E intake or vitamin E levels in body fluids and neurodegenerative diseases. Some studies concluded that vitamin E can play a protective role in neurodegeneration with respect to diseases such as Alzheimer's disease (AD), Parkinson's disease (PD), stroke and amyotrophic lateral sclerosis (ALS). Vitamin E supplementation was also associated with risk factors for some neurodegenerative diseases. In this review, we discuss the possible effects of vitamin E on the development and course of AD, PD, stroke and ALS, and the potential mechanisms involved. Vitamin E deficiency is associated with many neurological problems. Although the mechanisms of vitamin E action in neurodegenerative diseases are not clear, there are many possible mechanisms. Examples of such mechanisms are the protective effects of vitamin E against oxidative stress damage and its suppressive role in the expression of many genes involved in the development of neurodegeneration. Many studies have evaluated the relationship between vitamin E intake or vitamin E levels in body fluids and neurodegenerative diseases. Some studies concluded that vitamin E can play a protective role in neurodegeneration with respect to diseases such as Alzheimer&#x2019;s disease (AD), Parkinson&#x2019;s disease (PD), stroke and amyotrophic lateral sclerosis (ALS). Vitamin E supplementation was also associated with risk factors for some neurodegenerative diseases. In this review, we discuss the possible effects of vitamin E on the development and course of AD, PD, stroke and ALS, and the potential mechanisms involved.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Icer</LastName><ForeName>Mehmet Arif</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Gazi University , Faculty of Health Sciences , Nutrition and Dietetics Department , Ankara , Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arslan</LastName><ForeName>Neslihan</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Gazi University , Faculty of Health Sciences , Nutrition and Dietetics Department , Ankara , Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gezmen-Karadag</LastName><ForeName>Makbule</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Gazi University , Faculty of Health Sciences , Nutrition and Dietetics Department , Ankara , Turkey.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Poland</Country><MedlineTA>Acta Neurobiol Exp (Wars)</MedlineTA><NlmUniqueID>1246675</NlmUniqueID><ISSNLinking>0065-1400</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>1406-18-4</RegistryNumber><NameOfSubstance UI="D014810">Vitamin E</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020521" MajorTopicYN="N">Stroke</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014810" MajorTopicYN="N">Vitamin E</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>2</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>12</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>5</Month><Day>5</Day><Hour>6</Hour><Minute>56</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>5</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33949169</ArticleId><ArticleId IdType="doi">10.21307/ane-2021-003</ArticleId><ArticleId IdType="pii">exeley</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>